---
audienceLevel: patient
cancerTypes:
- colorectal
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Cetuximab - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/cetuximab
version: v1
---

# Cetuximab - NCI

# Cetuximab

Placeholder slot

(seh-TUK-sih-mab)

This page contains brief information about cetuximab (Erbitux) and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Erbitux

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9&audience=consumer)

## Use in Cancer

Cetuximab is approved to be used alone or with other drugs to treat:

- **[Colorectal cancer](/Common/PopUps/popDefinition.aspx?id=444983&version=Patient&language=English)** that has spread to other parts of the body. It is used:
- In patients whose cancer has the [EGFR](/Common/PopUps/popDefinition.aspx?id=44397&version=Patient&language=English) [protein](/Common/PopUps/popDefinition.aspx?id=46092&version=Patient&language=English) and the [wild-type KRAS gene](/Common/PopUps/popDefinition.aspx?id=785884&version=Patient&language=English). It is used:
- With [FOLFIRI](/Common/PopUps/popDefinition.aspx?id=635807&version=Patient&language=English) [combination chemotherapy](/Common/PopUps/popDefinition.aspx?id=45650&version=Patient&language=English) as the first treatment.
- With [irinotecan hydrochloride](/Common/PopUps/popDefinition.aspx?id=635811&version=Patient&language=English) in patients whose cancer was treated with chemotherapy that included irinotecan hydrochloride but it did not work or is no longer working.
- Alone in patients whose cancer did not respond to [oxaliplatin](/Common/PopUps/popDefinition.aspx?id=45465&version=Patient&language=English) and irinotecan hydrochloride or who cannot be treated with irinotecan hydrochloride.
- In adults whose cancer has a certain mutation in the *[BRAF](/Common/PopUps/popDefinition.aspx?id=561325&version=Patient&language=English)* gene. It is given with [encorafenib](/Common/PopUps/popDefinition.aspx?id=793869&version=Patient&language=English).
- **[Squamous cell carcinoma of the head and neck](/Common/PopUps/popDefinition.aspx?id=597171&version=Patient&language=English).** It is used:
- With [radiation therapy](/Common/PopUps/popDefinition.aspx?id=44971&version=Patient&language=English) in patients with [locally](/Common/PopUps/popDefinition.aspx?id=45955&version=Patient&language=English) or regionally [advanced](/Common/PopUps/popDefinition.aspx?id=478743&version=Patient&language=English) cancer.
- With [platinum](/Common/PopUps/popDefinition.aspx?id=45841&version=Patient&language=English) chemotherapy and [fluorouracil](/Common/PopUps/popDefinition.aspx?id=46090&version=Patient&language=English) in patients with locally or regionally recurrent cancer or [metastatic](/Common/PopUps/popDefinition.aspx?id=44058&version=Patient&language=English) cancer.
- Alone in patients with recurrent or metastatic cancer that got worse after platinum chemotherapy.

Cetuximab is also being studied in the treatment of other types of cancer.

## More About Cetuximab

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/42384) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Cetuximab](https://medlineplus.gov/druginfo/meds/a607041.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isnâ€™t an Option](https://www.cancer.gov/news-events/cancer-currents-blog/2024/head-neck-cancer-cetuximab-versus-durvalumab)

[Targeted Therapies to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Cetuximab](https://www.cancer.gov/research/participate/clinical-trials/intervention/C1723) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
